English | 简体中文 | 繁體中文 | 한국어 | 日本語
2022年3月2日 16時00分 JST
Share:
Avance Clinical Announces New Office Opening in Sydney

シドニー, 2022年3月2日 - (JCN Newswire) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region.

Avance Clinical's CEO Yvonne Lungershausen said: "We continue to offer a hybrid working environment for our team however, they are increasingly wanting more in-office face-to-face time with colleagues and clients - while still having the flexibility of working remotely".

"Avance is continuing to experience significant growth facilitating our expansion into North Sydney with new offices to accommodate our growing team," she said.

Check for our latest positions open and join our Sydney team here. https://www.avancecro.com/careers/

Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m.

"With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions," said Lungershausen.

Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.

The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies.

"We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.

Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.

Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/

For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/

About Avance Clinical

Avance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.

Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.

Media Contacts:
Avance Clinical
Chris Thompson
media@avancecro.com

トピック: Press release summary
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
三菱重工、南フランス・核融合実験炉イーター向けダイバータ外側垂直ターゲット12基を追加受注 
May 20, 2024 13:00 HKT/SGT
富士通、論理推論を可能とする大規模言語モデルの研究開発が「GENIAC」に採択 
May 17, 2024 14:00 HKT/SGT
Honda、将来のSDV実現に向け、IBMと次世代半導体・ソフトウェア技術の長期共同研究開発に関する覚書を締結 
May 15, 2024 10:00 HKT/SGT
富士通、スーパーコンピュータ「富岳」の世界ランキング結果を発表 
May 13, 2024 19:00 HKT/SGT
三菱重工など、電力系統の混雑緩和を実現するシステムのフィールド実証を開始 
May 10, 2024 11:50 HKT/SGT
ソニー独自のマイクロサージャリー支援ロボットを開発 
May 9, 2024 18:00 HKT/SGT
Honda、インドでの電動化の加速に向けた研究開発拠点をベンガルールに開設 
May 9, 2024 13:50 HKT/SGT
LEXUS、「LM」に6座仕様車を追加設定 
May 9, 2024 13:45 HKT/SGT
富士通、がんのタイプ分けなどのゲノム医療分野の課題を世界最高精度で解く、説明可能なAI技術を開発 
May 9, 2024 13:30 HKT/SGT
アフリカがついに日本のビジネスにおける国境を開放 
May 8, 2024 15:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575